In contrast, pharmacological inhibition of ATGL or ATGL disruption by CRISPR/Cas9 led to a more aggressive phenotype in parallel with increased intracellular TG content of lung cancer cell lines [195]. This evidence concerns the gene PNPLA2 and lung carcinoma.